BIOQUAL, INC.

BIOQUAL, INC. specializes in preclinical research and laboratory services supporting biomedical innovation, with deep expertise in nonhuman primate and rodent model studies for infectious disease, immunology, and metabolic research. The company conducts controlled in vivo experiments, performs detailed laboratory analyses of biological specimens, and manages specialized containment facilities, including ABSL-2/3 environments. Their technical capabilities encompass the design and execution of complex animal studies, humanized mouse model development, treatment protocol implementation, and high-precision data collection under strict regulatory oversight. BIOQUAL’s distinguishing strength lies in its ability to deliver end-to-end preclinical research services—from study design and animal husbandry to sample analysis and reporting—ensuring reproducibility and compliance with federal biosafety and animal welfare standards. The contractor maintains a consistent, long-standing relationship with the Department of Health and Human Services, particularly through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), where it supports mission-critical research on infectious diseases, metabolic disorders, and translational therapeutics. Work includes routine and specialized animal treatment studies, diagnostic testing, and facility maintenance for high-containment biocontainment environments, indicating a trusted role in supporting NIH-funded biomedical programs. BIOQUAL’s primary focus is in life sciences R&D, specifically under NAICS 541715 and 541714, which reflect advanced experimental research in infectious disease modeling and biotechnology applications excluding nanobiotechnology. Their market positioning centers on serving government-funded biomedical research initiatives requiring rigorous, GxP-aligned preclinical data generation. Based in Rockville, Maryland, BIOQUAL operates as a small business under the 2L entity structure. While no formal government certifications are listed, its sustained performance on high-compliance federal contracts demonstrates operational maturity in regulated research environments and a strategic alignment with the NIH and broader HHS research ecosystem.